Japan Liver Disease Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Antiviral Drugs, Vaccines, and Chemotherapy), By Disease (Hepatitis, and Autoimmune Diseases), and Japan Liver Disease Therapeutics Market Insights, Industry Trend, Forecasts to 2035

Japan Liver Disease Therapeutics Market Insights Forecasts to 2035

• The Japan Liver Disease Therapeutics Market Size Was Estimated at USD 1.58 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of Around 7.13% from 2025 to 2035
• The Japan Liver Disease Therapeutics Market Size is Expected to Reach USD 3.37 Billion by 2035

According to a Research Report Published by Spherical Insights & Consulting, The Japan Liver Disease Therapeutics Market Size is anticipated to Reach USD 3.37 Billion by 2035, Growing at a CAGR of 7.13% from 2025 to 2035. The Japan liver disease therapeutics market is driven by various factors, including, rising cases of hepatitis, alcohol related liver conditions, rising obesity, a rise in diabetes prevalence and advancement in drug developments.

Market Overview

The liver disease therapeutics include all the medicines, treatments that are used to prevent, manage or cure diseases related to the liver, including hepatitis, liver cirrhosis, fatty liver disease, and liver cancer. The increase in liver diseases due to various factors, such as a rise in alcohol consumption, over junk food consumption, primarily fuels market growth. Medical technological innovation in the diagnosis of liver diseases using imaging modalities, liver function tests, and biomarker-based diagnosis drives market expansion. The next-generation therapies are being developed with advancements in biologics, gene editing, and RNA sciences. Japan is now among the worlds most successful nations in the elimination of the hepatitis virus as a result of having very strong antiviral drugs and anti-hepatitis protocols available. The rising prevalence of non- alcoholic fatty liver disease due to an againg population leads high demand for quality NASH drugs, which presents an opportunity for manufacturers to develop effective drugs. Another opportunity that has arisen is the development of precision medicines instead of giving one treatment for all, giving treatment based on a persons characteristics.

Report Coverage

This research report categorizes the market for the Japan liver disease therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan liver disease therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan liver disease therapeutics market.

Driving Factors

The Japan liver disease therapeutics market is growing rapidly due to several factors. One of the primary driving factors is the rise in liver disease, such as viral hepatitis, non-alcoholic fatty liver disease, alcohol related liver disease and hepatocellular carcinoma heightened the clinical demand for liver therapeutics. The rise in obesity, diabetic patients, over alcohol consumption and unhealthy diets leads to liver disease, which expels the growth of this market. The therapeutic innovations, such as mRNA-based platforms, antiviral development and immune-modulating strategies, are significant market drivers for this market. Additionally, the advanced developments in diagnostics positively contribute to the growth of the market.

Restraining Factors

The Japan liver disease therapeutics market has several challenges that hinder its growth of the market.  One of the key limitations high cost of high-cost treatment, which limits access to low-income people. The side effects associated with liver disease treatment limit the market growth.

Market Segmentation

The Japan liver disease therapeutics market share is classified into product type and disease.

• The antiviral drugs segment dominated the market in 2024 and is expected to grow at a rapid CAGR during the forecast period.

The Japan liver disease therapeutics market is segmented by product type into antiviral drugs, vaccines, and chemotherapy. Among these, the antiviral drugs segment dominated the market in 2024 and is expected to grow at a rapid CAGR during the forecast period. The segmental growth is attributed to its efficacy in suppressing the infection and improving liver function. The rising prevalence for hepatitis B & C drives the growth of this segment.

• The hepatitis segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan liver disease therapeutics market is segmented by disease into hepatitis and autoimmune diseases. Among these, the hepatitis segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the rising burden of chronic hepatitis B and hepatitis C infections.

Competitive Analysis

The report offers the appropriate analysis of the key organizations or companies involved within the Japan liver disease therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Takeda Pharmaceutical Company
• Astellas Pharma
• Daiichi Sankyo
• Mitsubishi Tanabe Pharma
• Eisai
• AbbVie Inc
• Merck & Co., Inc.
• GlaxoSmithKline
• Bristol Myers Squibb
• Other

Recent Developments

• In June 2025, Takeda Pharmaceuticals launched LIVMARLI Oral Solution 10mgml for treating pruritus associated with cholestasis in Alagille syndrome and progressive familial intrahepatic cholestasis in Japan.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan liver disease therapeutics market based on the below-mentioned segments:

Japan Liver Disease Therapeutics Market, By Product Type

• Antiviral Drugs
• Vaccines
• Chemotherapy

Japan Liver Disease Therapeutics Market, By Disease

• Hepatitis
• Autoimmune Diseases